Citigroup Issues Pessimistic Forecast for Structure Therapeutics (NASDAQ:GPCR) Stock Price

Structure Therapeutics (NASDAQ:GPCR) had its price target dropped by stock analysts at Citigroup from $100.00 to $97.00 in a research report issued to clients and investors on Friday,Benzinga reports. The firm presently has a “buy” rating on the stock. Citigroup’s price target indicates a potential upside of 82.54% from the stock’s previous close.

Several other brokerages have also weighed in on GPCR. Canaccord Genuity Group set a $111.00 price objective on shares of Structure Therapeutics in a research report on Friday. Wall Street Zen upgraded shares of Structure Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 1st. HC Wainwright reduced their price objective on Structure Therapeutics from $100.00 to $70.00 and set a “buy” rating for the company in a report on Thursday, June 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Structure Therapeutics in a research note on Friday, July 17th. Finally, Citizens Jmp lowered their target price on Structure Therapeutics from $113.00 to $110.00 and set a “market outperform” rating on the stock in a research note on Friday. Three research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $110.91.

Structure Therapeutics Stock Up 1.0%

Shares of NASDAQ GPCR traded up $0.52 during midday trading on Friday, hitting $53.14. 328,648 shares of the company’s stock were exchanged, compared to its average volume of 893,274. The firm has a market capitalization of $3.78 billion, a PE ratio of -61.08 and a beta of -1.43. Structure Therapeutics has a 12 month low of $15.86 and a 12 month high of $94.90. The company’s 50 day moving average price is $47.36 and its 200 day moving average price is $54.20.

Structure Therapeutics (NASDAQ:GPCR) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.10). On average, equities research analysts anticipate that Structure Therapeutics will post -1.64 EPS for the current year.

Institutional Investors Weigh In On Structure Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Orbimed Advisors LLC grew its stake in Structure Therapeutics by 27.0% during the first quarter. Orbimed Advisors LLC now owns 1,475,403 shares of the company’s stock worth $71,114,000 after buying an additional 313,600 shares in the last quarter. Principal Financial Group Inc. raised its position in shares of Structure Therapeutics by 63.1% in the 4th quarter. Principal Financial Group Inc. now owns 1,284,210 shares of the company’s stock valued at $89,317,000 after buying an additional 496,726 shares in the last quarter. SEB Asset Management AB bought a new stake in shares of Structure Therapeutics during the 1st quarter worth approximately $11,811,000. Peregrine Capital Management LLC acquired a new stake in shares of Structure Therapeutics during the 4th quarter worth approximately $5,865,000. Finally, Siren L.L.C. boosted its position in shares of Structure Therapeutics by 23.2% during the 1st quarter. Siren L.L.C. now owns 1,328,698 shares of the company’s stock worth $64,043,000 after acquiring an additional 250,000 shares in the last quarter. 91.78% of the stock is currently owned by institutional investors and hedge funds.

About Structure Therapeutics

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.